Oculis (OCS) Competitors $21.00 -0.09 (-0.43%) Closing price 04:00 PM EasternExtended Trading$21.03 +0.03 (+0.14%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCS vs. XENE, CGON, QURE, RARE, APLS, IMVT, GMTX, OGN, MOR, and KNSAShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Xenon Pharmaceuticals (XENE), CG Oncology (CGON), uniQure (QURE), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), Gemini Therapeutics (GMTX), Organon & Co. (OGN), MorphoSys (MOR), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry. Oculis vs. Its Competitors Xenon Pharmaceuticals CG Oncology uniQure Ultragenyx Pharmaceutical Apellis Pharmaceuticals Immunovant Gemini Therapeutics Organon & Co. MorphoSys Kiniksa Pharmaceuticals International Oculis (NASDAQ:OCS) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends. Which has more volatility & risk, OCS or XENE? Oculis has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Does the media favor OCS or XENE? In the previous week, Oculis had 2 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 20 mentions for Oculis and 18 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.72 beat Oculis' score of 0.28 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 1 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of OCS or XENE? 22.3% of Oculis shares are owned by institutional investors. Comparatively, 95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. 4.1% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer OCS or XENE? Oculis currently has a consensus target price of $41.00, suggesting a potential upside of 95.24%. Xenon Pharmaceuticals has a consensus target price of $53.67, suggesting a potential upside of 34.20%. Given Oculis' higher possible upside, analysts clearly believe Oculis is more favorable than Xenon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60Xenon Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92 Is OCS or XENE more profitable? Xenon Pharmaceuticals has a net margin of 0.00% compared to Oculis' net margin of -13,958.12%. Xenon Pharmaceuticals' return on equity of -38.50% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-13,958.12% -90.31% -67.85% Xenon Pharmaceuticals N/A -38.50%-36.47% Which has preferable earnings & valuation, OCS or XENE? Oculis has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$780K1,175.46-$97.43M-$2.67-7.87Xenon Pharmaceuticals$7.50M411.13-$234.33M-$3.55-11.26 SummaryXenon Pharmaceuticals beats Oculis on 11 of the 17 factors compared between the two stocks. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$916.86M$3.33B$6.04B$10.44BDividend YieldN/A2.31%5.73%4.79%P/E Ratio-7.8722.2285.3127.07Price / Sales1,175.46439.84588.57190.17Price / CashN/A44.9825.7330.17Price / Book10.9910.3812.666.69Net Income-$97.43M-$52.31M$3.31B$276.03M7 Day Performance13.15%0.59%-0.44%-1.13%1 Month Performance20.69%13.90%8.70%6.49%1 Year Performance41.03%28.95%76.70%34.41% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis2.8662 of 5 stars$21.00-0.4%$41.00+95.2%+41.6%$916.86M$780K-7.872Analyst RevisionXENEXenon Pharmaceuticals2.452 of 5 stars$39.55-0.2%$53.30+34.8%-3.8%$3.05B$7.50M-11.14210CGONCG Oncology2.1658 of 5 stars$38.13-4.2%$56.55+48.3%+19.8%$3.04B$1.14M-21.5461Insider TradeQUREuniQure3.2406 of 5 stars$52.91-3.7%$71.75+35.6%+989.6%$3.01B$27.12M-13.50500RAREUltragenyx Pharmaceutical4.3425 of 5 stars$30.19-3.3%$81.50+170.0%-42.9%$3.01B$610.16M-5.461,294APLSApellis Pharmaceuticals4.0584 of 5 stars$24.36+2.4%$33.29+36.7%-7.3%$3.01B$754.65M-13.38770IMVTImmunovant2.1534 of 5 stars$16.55-2.1%$33.20+100.6%-44.0%$2.95BN/A-5.81120GMTXGemini TherapeuticsN/A$67.78+2.9%N/A+46.4%$2.94BN/A-67.7830OGNOrganon & Co.4.798 of 5 stars$10.84-1.5%$17.33+59.9%-46.8%$2.86B$6.40B4.034,000MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730KNSAKiniksa Pharmaceuticals International3.8867 of 5 stars$38.29-0.5%$44.29+15.7%+42.7%$2.85B$423.24M957.49220Analyst Forecast Related Companies and Tools Related Companies XENE Competitors CGON Competitors QURE Competitors RARE Competitors APLS Competitors IMVT Competitors GMTX Competitors OGN Competitors MOR Competitors KNSA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCS) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
